Comparing new treatments for Clostridioides difficile infection
Comparative Efficacy of Therapeutics for Clostridioides difficile Infection
This study is testing a new daily pill that aims to help people with Clostridioides difficile infection without using traditional antibiotics, so it can keep your gut healthy while reducing the chances of the infection coming back.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-11007011 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a novel oral therapeutic designed to treat Clostridioides difficile infection (CDI) without using traditional antibiotics. CDI often occurs after antibiotic use disrupts the gut microbiome, leading to severe gastrointestinal issues. The study aims to evaluate a first-in-class immunoregulatory treatment that preserves the microbiome and reduces infection recurrence. Patients will be monitored for safety and efficacy as they receive this new therapy, which is designed to be taken once daily.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Clostridioides difficile infection, particularly those who have experienced recurrent infections.
Not a fit: Patients who are not diagnosed with CDI or those who have contraindications to the investigational therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients suffering from CDI, reducing reliance on antibiotics.
How similar studies have performed: Other research has shown promise in using novel, non-antibiotic therapies for CDI, indicating a growing interest and potential in this area.
Where this research is happening
Blacksburg, United States
- Biotherapeutics, INC. — Blacksburg, United States (Active)
Researchers
- Principal investigator: Hontecillas, Raquel — Biotherapeutics, INC.
- Study coordinator: Hontecillas, Raquel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.